Making the Switch from Biologics to Biosimilars in IBD: Knowledge Over SkepticismPremiere Date: Monday, January 24, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, January 24, 2023
|Edward V. Loftus, Jr., MD (Moderator)
Professor of Medicine
Mayo Clinic College of Medicine
Co-Director, Advanced IBD Fellowship
Mayo Graduate School of Medicine
Consultant, Division of Gastroenterology and Hepatology
|Shubha Bhat, PharmD, MS, BCACP
Clinical Pharmacy Specialist, Gastroenterology
Digestive Disease & Surgery Institute
|Christina Ha, MD, FACG, AGAF
Inflammatory Bowel Disease Center
The management of chronic autoimmune diseases such as inflammatory bowel disease (IBD) is often accomplished with the utilization of biologic agents. However, new biosimilars are emerging for the treatment of IBD. These biosimilars are molecules highly similar to approved biologic medicines and are comprehensively developed and rigorously tested to ensure that efficacy and safety are similar to the reference product. Unfortunately, both clinicians and patients lack knowledge of biosimilar efficacy and safety, which leads to fewer clinicians prescribing them and patients experiencing feelings of uncertainty and ungrounded negative perceptions toward receiving biosimilars.
This CME Outfitters OnDemand symposium from the Crohn’s & Colitis Congress 2022 features an expert panel discussion that defines biosimilar terminology, presents clinical trial data and real-world evidence on the efficacy and safety of biosimilars, and details team-based strategies for enhancing patient-clinician shared decision-making (SDM) regarding the use of biosimilars.
At the end of this CE activity, participants should be able to:
- Define terminology related to biosimilar products, including interchangeability, substitution, and switching.
- Assess the efficacy and safety of biosimilars via clinical trial data and real-world evidence in regard to treatment selection for patients with IBD.
- Implement team-based strategies to enhance patient-clinician SDM regarding the use of biosimilars.
This activity is supported by educational funding provided by Amgen.
Gastroenterologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
AGA Disclosure Statement:
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Dr. Loftus reports the following financial relationships:
Consultant for AbbVie Inc.; Amgen Inc; Arena Pharmaceuticals; Boehringer Ingelheim; Bristol Myers Squibb; Calibr - California Institute for Biomedical Research; Celgene Corporation; Eli Lilly; Genentech; Gilead Sciences, Inc; Gossamer Bio; Iterative Scopes, Inc; Janssen Therapeutics; Ono Pharmaceutical CO., LT; Pfizer Inc; Scipher Medicine Corporation; Sunovion Pharmaceuticals, Inc; Takeda Pharmaceutical Company Limited; and UCB, Inc.
Other financial or material support as Chief Medical Editor, Healio
Research support from AbbVie Inc.; BIOCOM CRO (Roberts Clinical Trials); Bristol Myers Squibb; Celgene Corporation; Genentech; Gilead Sciences, Inc.; Gossamer Bio; Janssen Therapeutics; Pfizer Inc; Receptos; Takeda Pharmaceutical Company Limited; Theravance; and UCB, Inc.
Stock shareholder (directly purchased) in Exact Sciences Corporation
Dr. Bhat has no disclosures to report.
Dr. Ha reports the following financial relationships:
Consultant and advisory boards for AbbVie, Inc.;BristolMyers Squibb; Genentech; Index Pharmaceuticals; Janssen; PfizerInc.; and Takeda
Educational grant from Pfizer Inc.
Non-funded research support from AbbVie Inc.; Eli Lilly; Genentech; and Pfizer Inc.
Thedra White (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Susan H. Yarbrough, CHCP (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).